GNQWFI

GNQWFI, an anti-Flt1 peptide, is a VEGFR1-specific antagonist. GNQWFI blocks the interaction of VEGFR1 with various VEGFR1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases[1].

853995-60-5

12352209

VEGFR

Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer; Cardiovascular Disease

99.45

DMSO : 50 mg/mL (ultrasonic)

CC[C@H](C)[C@@H](C(O)=O)NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](CC(N)=O)NC(CN)=O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O

C37H49N9O9

763.84

[1]Oh EJ, et al. Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization. Biomaterials. 2009 Oct;30 (30) :6026-34.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10831/GNQWFI-SDS-MedChemExpress.pdf

Peptides

No Development Reported

VEGFR1/Flt-1